Periodic evaluation of endogenous insulin secretion is necessary, and basic pharmacotherapy should be performed in accordance with the treatment guidelines for type 2 diabetes, except for the use of sulfonylurea agents. The gene discussed is INS; the disease is type 2 diabetes mellitus.